Genome-wide analysis of electroacupuncture in restoring splicing regulation after myocardial ischemia-reperfusion injury

Abstract

Objective: Pre-mRNA alternative splicing (AS) is an important post-transcriptional regulation mechanism. The abnormal splicing of genes can lead to cardiovascular diseases. Acupuncture has been shown to alleviate myocardial ischemia-reperfusion injury (MIRI), but most studies have focused on the regulation of gene expression by acupuncture. Previously, we reported that electroacupuncture (EA) can relieve angina by regulating the AS of GABARG2; however, the genome-wide regulation of AS by EA remains unknown. Methods: We explored the protective effects of EA on MIRI. We then studied the AS profiles retrieved from the previously submitted to Gene Expression Omnibus (GEO) database and analyzed the data using the replicate multivariate analysis of transcript splicing (rMATS) tool. Subsequently, we conducted validation experiments on splicing regulatory factors and their target genes modulated by EA, as identified through bioinformatics analysis. Results: The results showed that EA at PC6 point could effectively alleviate MIRI. More than 200 differential alternative splicing events (ASEs) changed following MIRI. The differential ASEs underwent protein–protein interaction (PPI) network analysis, gene ontology (GO) enrichment, and pathway analysis, and were shown to be involved in distinct biological functions, especially in the maintenance of synaptic structure. Enrichment analysis also identified several pathways that are potentially associated with the progression of MIRI. Importantly, we identified critical ASEs and pathways that could be completely rescued by EA treatment. In the validation experiments, we found that AS of the key gene CAMK2G, associated with synaptic function, is regulated by the expression level of the MBNL1 protein modulated by EA. Conclusions: Our results indicate that EA is not only an effective procedure to protect against MIRI by rescuing gene expression but also rescues abnormal ASEs. This study is a major contribution to a genome-wide comprehensive analysis of the regulation of AS by EA in MIRI.

Keywords

Alternative splicing / Alternative splicing events / Electroacupuncture / MIRI / rMATS

References

[1] Maniatis T, Tasic B. Alternative pre—mRNA splicing and proteome expansion in metazoans. Nature 2002; 418: 236-243.

[2] Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476.

[3] Johnson JM, Castle J, Garrett—Engele P, et al. Genome—wide survey of human alternative pre—mRNA splicing with exon junction microarrays. Science 2003; 302: 2141-2144.

[4] Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high—throughput sequencing. Nat Genet 2008; 40: 1413-1415.

[5] Stamm S, Ben—Ari S, Rafalska I, et al. Function of alternative splicing. Gene 2005; 344: 1-20.

[6] van den Hoogenhof MM, Pinto YM, Creemers EE. RNA splicing: regulation and dysregulation in the heart. Circ Res 2016; 123: 454-468.

[7] Kalsotra A, Xiao X, Ward AJ, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 2008; 105: 20333-20338.

[8] Lara—Pezzi E, Gomez—Salinero J, Gatto A, et al. The alternative heart: impact of alternative splicing in heart disease. J Cardiovasc Transl Res 2013; 6: 945-955.

[9] Watanabe T, Kimura A, Kuroyanagi H. Alternative splicing regulator RBM20 and cardiomyopathy. Front Mol Biosci 2018; 5: 105.

[10] Dlamini Z, Tshidino SC, Hull R. Abnormalities in alternative splicing of apoptotic genes and cardiovascular diseases. Int J Mol Sci 2015; 16: 27171-27190.

[11] Wahbi K, Algalarrondo V, Becane HM, et al. Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1. Arch Cardiovasc Dis 2013; 106: 635-643.

[12] Kong SW, Hu YW, Ho JW, et al. Heart failure—associated changes in RNA splicing of sarcomere genes. Circ Cardiovasc Genet 2010; 3: 138-146.

[13] Ni YM, Frishman WH. Acupuncture and cardiovascular disease: focus on heart failure. Cardiol Rev 2018; 26: 93-98.

[14] Wang K, Tang M, Ouyang L, et al. Acupuncture for heart disease patients. Eur J Prev Cardiol 2018; 25: 1116.

[15] Zhao L, Li D, Zheng H, et al. Acupuncture as adjunctive therapy for chronic stable angina: a randomized clinical trial. JAMA Intern Med 2019; 179: 1388-1397.

[16] Lee H, Kim TH, Leem J. Acupuncture for heart failure: a systematic review of clinical studies. Int J Cardiol 2016; 222: 321-331.

[17] Yuan J, Wang JM, Cai Y, et al. Correlation between ischemic myocardial injury and inflammatory reaction, and anti—inflammatory effect of acupuncture. Zhen Ci Yan Jiu 2019; 4: 302-306.

[18] Li Y, Xiang Y, Liang J, et al. The mechanism and treatment strategies of GSDMD—mediated proptosis in myocardial infarction. Acupunct Herb Med 2024; 4(3): 295-305.

[19] Zhang XL, Huang W, Yang QQ, et al. Effect of electroacupuncture preconditioning on cell apoptosis mediated by mitochondrial reactive oxygen species in myocardial ischemia/reperfusion injury rats. Zhen Ci Yan Jiu 2020; 12: 961-967.

[20] Huang J, Yan J, Wang T, et al. Research progress on central autonomic nervous mechanism of acupuncture at Neiguan point in the treatment of atrial fibrillation. Acupunct Herb Med 2023; 3(3): 149-157.

[21] Zhang J, Zhu L, Li H, et al. Electroacupuncture pretreatment as a novel avenue to protect heart against ischemia and reperfusion injury. Evid Based Complement Alternat Med 2020; 2020: 9786482.

[22] Qi W, Fu H, Luo X, et al. Electroacupuncture at PC6 (Neiguan) attenuates angina pectoris in rats with myocardial ischemia—reperfusion injury through regulating the alternative splicing of the major inhibitory neurotransmitter receptor GABRG2. J Cardiovasc Transl Res 2022; 15(5): 1176-1191.

[23] Jiang W, Chen L. Alternative splicing: human disease and quantitative analysis from high—throughput sequencing. Comput Struct Biotechnol J 2021; 19: 183-195.

[24] Shen S, Park JW, Lu ZX, et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA—Seq data. Proc Natl Acad Sci U S A 2014; 51: E5593-E5601.

[25] Huang Y, Lu SF, Hu CJ, et al. Electro—acupuncture at Neiguan pretreatment alters genome—wide gene expressions and protects rat myocardium against ischemia—reperfusion. Molecules 2014; 19: 16158-16178.

[26] Kane KA, Parratt JR, Williams FM. An investigation into the characteristics of reperfusion—induced arrhythmias in the anaesthetized rat and their susceptibility to antiarrhythmic agents. Br J Pharmacol 1984; 82(2): 349-357.

[27] Giulietti M, Piva F, D’Antonio M, et al. SpliceAid—F: a database of human splicing factors and their RNA—binding sites. Nucleic Acids Res 2013; 41(Database issue): D125-D131.

[28] Van Nostrand EL, Freese P, Pratt GA, et al. A large—scale binding and functional map of human RNA—binding proteins. Nature 2020; 583: 711-719.

[29] Wu JY, Kar A, Kuo D, et al. SRp54 (SFRS11), a regulator for tau exon 10 alternative splicing identified by an expression cloning strategy. Mol Cell Biol 2006; 18: 6739-6747.

[30] Grammatikakis I, Zhang P, Panda AC, et al. Alternative splicing of neuronal differentiation factor TRF2 regulated by HNRNPH1/H2. Cell Rep 2016; 15: 926-934.

[31] Zhou H, Mangelsdorf M, Liu J, et al. RNA—binding proteins in neurological diseases. Sci China Life Sci 2014; 57: 432-444.

[32] Furuta M, Kimura T, Nakamori M, et al. Macroscopic and microscopic diversity of missplicing in the central nervous system of patients with myotonic dystrophy type 1. Neuroreport 2018; 29: 235-240.

[33] Traunmuller L, Gomez AM, Nguyen TM, et al. Control of neuronal synapse specification by a highly dedicated alternative splicing program. Science 2016; 352: 982-986.

[34] Prando V, Da BF, Franzoso M, et al. Dynamics of neuroeffector coupling at cardiac sympathetic synapses. J Physiol 2075; 2018(11): 2055.

[35] Zhang H, He L, Cai L. Transcriptome sequencing: RNA—Seq. Methods Mol Biol 2018; 175: 15-27.

[36] Li Y, Barajas—Martinez H, Li B, et al. Comparative effectiveness of acupuncture and antiarrhythmic drugs for the prevention of cardiac arrhythmias: a systematic review and meta—analysis of randomized controlled trials. Front Physiol 2017; 8: 358.

[37] Ji C, Song F, Huang G, et al. The protective effects of acupoint gel embedding on rats with myocardial ischemia—reperfusion injury. Life Sci 2018; 211: 51-62.

[38] Meng J. The effects of acupuncture in treatment of coronary heart diseases. J Tradit Chin Med 2004; 1: 16-19.

[39] Pianca N, Di Bona A, Lazzeri E, et al. Cardiac sympathetic innervation network shapes the myocardium by locally controlling cardiomyocyte size through the cellular proteolytic machinery. J Physiol 2019; 597: 3639-3656.

[40] Lee SH, Kim DH. Synapses in the heart: sympathetic neuro—cardiac interaction modulates myocardial remodelling in healthy and diseased myocardium. J Physiol 2019; 597: 4441-4442.

[41] Middlekauff HR, Hui K, Yu JL, et al. Acupuncture inhibits sympathetic activation during mental stress in advanced heart failure patients. J Card Fail 2002; 8: 399-406.

[42] Middlekauff HR. Acupuncture in the treatment of heart failure. Cardiol Rev 2004; 12: 171-173.

[43] Zhu C, Chen Z, Guo W. Pre—mRNA mis—splicing of sarcomeric genes in heart failure. Biochim Biophys Acta Mol Basis Dis 2017; 1863: 2056-2063.

[44] Hermey G, Bluthgen N, Kuhl D. Neuronal activity—regulated alternative mRNA splicing. Int J Biochem Cell Biol 2017; 91: 184-193.

[45] Ovando—Roche P, Yu JS, Testori S, et al. TRF2—mediated stabilization of hREST4 is critical for the differentiation and maintenance of neural progenitors. Stem Cells 2014; 32: 2111-2122.

[46] Trujillo CA, Rice ES, Schaefer NK, et al. Reintroduction of the archaic variant of NOVA1 in cortical organoids alters neurodevelopment. Science 2021; 371: eaax2537.

[47] Zhang W, Dong E, Zhang J, et al. CaMK2, “jack of all trades” in inflammation during cardiac ischemia/reperfusion injury. J Mol Cell Cardiol 2023; 184: 48-60.

[48] Sloutsky R, Stratton MM. Functional implications of CaMK2 alternative splicing. Eur J Neurosci 2021; 54(8): 6780-6794.

[49] Jia K, Cheng H, Ma W, et al. RNA Helicase DDX5 maintains cardiac function by regulating CaMK2δ alternative splicing. Circulation 2024; 150: 1121-1139.

[50] Duran J, Nickel L, Estrada M, et al. CaMK2δ splice variants in the healthy and diseased heart. Front Cell Dev Biol 2021; 9: 644630.

[51] Bell JR, Raaijmakers AJ, Curl CL, et al. Cardiac CaMK2δ splice variants exhibit target signaling specificity and confer sex—selective arrhythmogenic actions in the ischemic—reperfused heart. Int J Cardiol 2015; 181: 288-296.

[52] Yasuda R, Hayashi Y, Hell JW. CaMK2: a central molecular organizer of synaptic plasticity, learning and memory. Nat Rev Neurosci 2022; 23(11): 666-682.

[53] Cook SG, Bourke AM, O’Leary H, et al. Analysis of the CaMK2α and β splice—variant distribution among brain regions reveals isoform—specific differences in holoenzyme formation. Sci Rep 2018; 8(1): 5448.

[54] Kim K, Saneyoshi T, Hosokawa T, et al. Interplay of enzymatic and structural functions of CaMK2 in long—term potentiation. J Neurochem 2016; 139(6): 959-972.

[55] Liu J, Wang K, Liu X, et al. RBM24 controls cardiac QT interval through CaMK2δ splicing. Cell Mol Life Sci 2022; 79(12): 613.

[56] Williams AL, Walton CB, Pinell B, et al. Ischemic heart injury leads to HIF1—dependent differential splicing of CaMK2γ. Sci Rep 2021; 11(1): 13116.

[57] Chen B, Xie K, Zhang J, et al. Comprehensive analysis of mitochondrial dysfunction and necroptosis in intracranial aneurysms from the perspective of predictive, preventative, and personalized medicine. Apoptosis 2023; 28(9—10): 1452-1468.